Register for our free email digests:
Latest From CStone Pharmaceuticals Co. Ltd.
Delinking drug approvals from price agreements, and providing timely and adequate reimbursement coverage, are just some of the policy changes top big pharma executives would like to see if China is to create an operating environment conducive to innovation.
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.
- Therapeutic Areas
- Parent & Subsidiaries
- Novogen Ltd.
- Senior Management
James Garner, MD, CEO
Cristyn Humphreys, CFO
David Brown, PhD, CSO
Peng Leong, PhD, CBO
- Contact Info
Phone: (61) 2 9472 4101
P.O. Box 2333 Hornsby Westfield, NSW 1635
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.